Clinical Trials Browser

Phase 1/2 × Interventional × Clinical Trials, Phase I as Topic × Clear all

NCT06839456 2026-04-15

Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT

Classical hematologyLymphoidOther hematologic neoplasm

Bone Marrow Failure Disorders, Congenital Bone Marrow Failure Syndromes, Anemia, Refractory, with Excess of Blasts, Hemoglobinopathies, Immunologic Deficiency Syndromes, Leukemia, Lymphoma, Non-Hodgkin, Metabolism, Inborn Errors

Clinical Trials

Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT

Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56

FIL_PTCL13

Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors

A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC

Study of Poziotinib in Japanese Patients With NSCLC

Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC

Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia

Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer

S 81694 Plus Paclitaxel in Metastatic Breast Cancer

Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC